Replies to post #340154 on Amarin Corp Plc (AMRN)

[sts66]

NOBODY replied to your post in the last 5 hrs?!? Hard to believe - I glanced over it, found what I thought were some glaring flaws in Hikma's arguments (Du followed Graham, which she certainly did not), but I was pretty unhappy with some of AMRN's expert testimony being used to further Hikma's points - AMRN shot itself in the foot multiple times - how the hell did Covington let this happen? Mori is the complete focus of Hikma's response with a brief mention of Hyashi, and Kurabyashi was totally ignored, no mention of it. Don't recall off the top of my head if Waxman's brief went hard after Kura, but pretty sure he went after Mori. I hate to be Debbie Downer, but if I knew nothing about this case, reading Hikma's response was pretty convincing about obviousness of the patents.

[oneragman]

sstyles, Hikma's attorneys did a good job on Prima Facia obviousness as it pertains to EPA and the trigs 200-500 population. IMO, AMRN's rebuttal needs to focus on the weighting of Objective Indices, especially where they weighted in favor of the defendants as well as rebutting the patient population. They need to hammer home that the >500 population was distinct as due to a genetic condition. The odds still favor Hikma.
Someone had recently posted where Du said in her decision it was close. I don't recall that and I don't have time to go back and read the decision again. but Hikma kept hammering that it wasn't close. If Du did indeed say it was close, that needs to be pointed out.